Verge and Collaborators Identify Digital Clinical Biomarker Endpoints Sensitive to Short Term Disease Progression in the Pre-treatment Run-in Period of VRG50635 Proof-of-Concept ALS Clinical Trial Press ReleaseRob MaguireApril 7, 2025
Verge Genomics' CMO, Diego Cadavid, will be presenting at the 77th Annual Meeting of the American Academy of Neurology (AAN) EventsRob MaguireApril 3, 2025
Irene Choi, PhD, to present at Keystone Symposia on MASH Pathogenesis and Therapeutic Approaches EventsRob MaguireFebruary 24, 2025
Anil Tarachandani set to share experience with collecting Actigraphy data to measure mobility and activity in ALS participants in VRG50635-002 clinical study at the Actigraph Digital Data Summi EventsRob MaguireFebruary 9, 2025
Alice Zhang and Irene Choi to Attend the 1st ANNUAL BIOPHARMA OBESITY INNOVATION FORUM EventsRob MaguireJanuary 10, 2025
Verge Genomics Announces New Development Candidate, VRG201, a Novel Maintenance Therapy for Long-Term Weight Management Press ReleaseRob MaguireDecember 16, 2024
Verge Genomics Announces Milestones in Collaboration with Lilly to Discover and Develop Novel Treatments for ALS Press ReleaseRob MaguireNovember 20, 2024
Géraldine Gontier & Grace Kim will be presenting insights from the VGCS-50635-002 study EventsRob MaguireOctober 24, 2024
Verge CEO Alice Zhang to be keynote speaker at the Longevity Platinum Trip EventsRob MaguireOctober 10, 2024
Diego Cadavid to present at 149th Annual Meeting of the American Neurological Association EventsRob MaguireSeptember 13, 2024
Verge Genomics CEO: Why I urge my employees to share their fears and vulnerabilities—and do the same with them NewsRob MaguireJune 6, 2024
Verge Genomics and Ferrer Announce Agreement to Co-Develop Clinical-Stage ALS Therapy VRG50635 Press ReleaseRob MaguireMarch 25, 2024
Verge Genomics to Present at Evercore ISI 2024 Emerging Biotech Conference Press ReleaseRob MaguireFebruary 21, 2024
Getting the most out of digital endpoints: case studies from Verge’s CMO NewsRob MaguireFebruary 15, 2024
Verge Genomics Announces Initiation of Proof-of-Concept Study for the Treatment of Amyotrophic Lateral Sclerosis (ALS) with VRG50635 Press ReleaseRob MaguireJanuary 9, 2024
